Funding for this research was provided by:
Ministry of Health and Welfare (HI14C3418)
Text and Data Mining valid from 2020-02-18
Received: 5 August 2019
Accepted: 31 January 2020
First Online: 18 February 2020
Ethics approval and consent to participate
: The study was approved by the committee of Samsung Medical Center (SMC), Seoul, Republic of Korea (IRB file #201004004), on the use of human samples for experimental studies. Written informed consent was obtained from all study participants prior to enrollment. The research conformed to the principles of the Helsinki Declaration.
: Written informed consent was obtained from all study participants prior to enrollment.
: Do-Hyun Nam is the CEO of AimedBio Inc. and owns shares of AimedBio Inc. which owns IPs for Avatascan. The remaining authors declare that they have no competing interests.